Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)   14

The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest unitl further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 will be accepted. While we regret this action, it is required to focus BARDA's efforts on the immediate need.

The latest BARDA BAA is amendment 13 posted on March 4, 2020.

All Areas of Interest are suspended except:

a. AOI 7.7.1 Diagnostic Assay for human coronavirus using existing FDA-cleared platforms,

b. AI 7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus

c. AOI 7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)

d. AOI 8.3 COVID-19 Vaccine,

e. AOI 9.2 COVID-19 Therapeutics,

f. AOI 9.3 Immunomodulators or therapeutics targeting lung repair, and

g. AOI 9.5 Pre-exposure and Post-exposure Prophylaxis,

h. AOI 10 Respiratory Protective Devices,

i. AOI 11 Ventilators.

BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

Background
This Broad Agency Announcement (BAA) sets forth advanced development areas of interest for the Office of Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). BARDA is the lead federal agency for supporting advanced development of medical countermeasures (MCM) to protect the United States against public health emergency threats, including CBRN agents, emerging infectious diseases, and pandemic influenza. The BAA is issued under paragraph 6.102(d)(2) of the Federal Acquisition Regulation, and proposals selected for award are considered to be the result of full and open competition and in full compliance with The Competition in Contracting Act of 1984, 41 U.S.C. 253.

Work Details
The mission of BARDA’s Antibacterials Program is to minimize the morbidity and mortality caused by multidrug-resistant organisms (MDROs) and biothreat pathogens. Critical to national preparedness is the availability of safe and effective antimicrobial drugs for all patient populations. BARDA is seeking therapeutics that will improve preparedness and response against toxins and viruses that pose a threat to the American public. Candidates must demonstrate efficacy against anthrax, botulism, smallpox or filoviruses as summarized in 2.1-2.4.
BARDA is also interested in such candidates that have potential for broad activity against multiple toxins, toxin classes, viruses, virus genera or virus families.

Period of Performance
The final white paper submission deadline is September 25, 2023, at 4:30 PM Eastern Time. The final full proposal submission deadline is September 25, 2023, at 4:30 PM Eastern Time for open areas of interest or as specified in the invitation letter.